Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
20.3M
-
Shares change
-
+705K
-
Total reported value, excl. options
-
$122M
-
Value change
-
+$4.44M
-
Put/Call ratio
-
0.9
-
Number of buys
-
41
-
Number of sells
-
-13
-
Price
-
$6.00
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q3 2021
78 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q3 2021.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.3M shares
of 77M outstanding shares and own 26.31% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.21M shares), Carmignac Gestion (2.48M shares), ACT Capital, L.L.C. (2.47M shares), VANGUARD GROUP INC (2.18M shares), ACUTA CAPITAL PARTNERS, LLC (1.32M shares), TWO SIGMA ADVISERS, LP (1.01M shares), TWO SIGMA INVESTMENTS, LP (827K shares), MORGAN STANLEY (807K shares), BlackRock Inc. (804K shares), and GEODE CAPITAL MANAGEMENT, LLC (487K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.